Cancer in Czechia

IARC estimates 65,308 new cancer cases and 28,845 cancer deaths in Czechia in 2024; the commonest new cancers are breast, colorectum and prostate. This page is assembled automatically from OnCo's data: 516 trials with a site there, 6 institutions, 3 companies, 7 people and 1 programme or law, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

65,308

all cancers

Deaths

28,845

all cancers

Incidence rate

281.9

per 100,000, age-standardised

Mortality rate

101.8

per 100,000, age-standardised

Cumulative risk

28.2%

of a cancer by age 74

Population

10,735,864

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Breast	7,598	72.2	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Colorectum	7,565	30.1	Colorectal cancer
Prostate	7,491	69.9	Prostate cancer
Trachea, bronchus and lung	6,293	24.3	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Bladder	3,258	12.2	Bladder & urothelial cancer
Kidney	3,122	13.7	Renal cell carcinoma
Melanoma of skin	3,002	14.5	Melanoma
Pancreas	2,590	9.9	Pancreatic ductal adenocarcinoma
Non-Hodgkin lymphoma	1,870	8.4	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Corpus uteri	1,863	15.8	Endometrial cancer

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	5,219	18.5	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	3,610	12.2	Colorectal cancer
Pancreas	2,516	8.8	Pancreatic ductal adenocarcinoma
Breast	1,746	11.6	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	1,626	11.1	Prostate cancer
Bladder	1,096	3.2	Bladder & urothelial cancer
Kidney	986	3.4	Renal cell carcinoma
Stomach	959	3.5	Gastric & gastro-oesophageal junction cancer
Liver and intrahepatic bile ducts	954	3.4	Hepatocellular carcinoma
Leukaemia	950	3.1	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Czechia”, in Eastern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

516 trials in OnCo · 132 recruiting overall

516 trials

Trial			Lead sponsor
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis NCT04910685	Phase 2/3	Recruiting	Blueprint Medicines Corporation	88	2026-10-07
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581	Phase 3	Recruiting	Eli Lilly and Company	416	2026-10-07
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract NCT07218380	Phase 3	Recruiting	Eli Lilly and Company	276	2026-10-07
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa NCT06091865	Phase 3	Recruiting	Regeneron Pharmaceuticals	194	2026-10-07
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, NCT06820463	Phase 2	Recruiting	AbbVie	75	2026-10-07
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant NCT06149286	Phase 3	Recruiting	Regeneron Pharmaceuticals	171	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML NCT07007312	Phase 3	Recruiting	Kura Oncology, Inc.	122	2026-10-07
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598	Phase 3	Recruiting	Eli Lilly and Company	366	2026-10-07
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer NCT06510374	Phase 3	Recruiting	Ferring Pharmaceuticals	112	2026-10-07
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) NCT07489495	Phase 3	Recruiting	Merck Sharp & Dohme LLC	99	2026-10-06
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737	Phase 3	Recruiting	Merck Sharp & Dohme LLC	298	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc NCT07216703	Phase 3	Recruiting	Merck Sharp & Dohme LLC	180	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558	Phase 3	Recruiting	Merck Sharp & Dohme LLC	165	2026-10-06
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) NCT04256317	Phase 2/3	Recruiting	Taiho Oncology, Inc.	73	2026-10-06
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	64	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354	Phase 3	Recruiting	Merck Sharp & Dohme LLC	281	2026-10-06
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult NCT07059845	Phase 2	Recruiting	AbbVie	85	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu NCT05533775	Phase 1/2	Recruiting	Hoffmann-La Roche	30	2026-10-06
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl NCT06824467	Phase 3	Recruiting	Merck Sharp & Dohme LLC	197	2026-10-06
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy NCT06091254	Phase 3	Recruiting	Regeneron Pharmaceuticals	190	2026-10-06
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) NCT03328078	Phase 1/2	Recruiting	Curis, Inc.	45	2026-10-06
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164	Phase 3	Recruiting	Merck Sharp & Dohme LLC	54	2026-10-06
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC NCT06216301	Phase 3	Recruiting	NovoCure GmbH	104	2026-10-06
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287 NCT06422143	Phase 3	Recruiting	Merck Sharp & Dohme LLC	216	2026-10-06
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer NCT07228832	Phase 3	Recruiting	Summit Therapeutics	236	2026-10-06

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Czechia, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Czechia is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

6 institutions

European Society of Gynaecological Oncology Institute of Applied Psychology (Czech Republic)Institute of Biostatistics and Analyses, Masaryk University Liga proti rakovině Praha Masaryk Memorial Cancer Institute Motol University Hospital

3 companies

Lipidica MAIA Labs SOTIO Biotech

7 people

People whose main affiliation in OnCo is an institution or company in Czechia.

Ane Gerda Eriksson Igor Kiss Jalid Sehouli Ladislav Dušek Marek Svoboda Petr Polouček Tomáš Kazda

Screening, vaccination and law

Term

Colorectal cancer screening programme in Czechia

Czechia runs a national colorectal cancer screening programme started in 2000, offering faecal immunochemical test (FIT) and colonoscopy, as recorded by IARC's CanScreen5 survey (2016).

Approvals

Czechia is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Czechia's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Czechia, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Czechia's own sources, beyond the programme records above.

A deep dive for Czechia is ranked 30 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/cz.json; every country: /api/v1/countries.json.